| COVID-19 vaccines currently under preclinical and clinical studies, and associated antiviral immune response S Jain, H Batra, P Yadav, S Chand Vaccines 8 (4), 649, 2020 | 61 | 2020 |
| Salmonella Engages Host MicroRNAs To Modulate SUMOylation: a New Arsenal for Intracellular Survival S Verma, G Mohapatra, SM Ahmad, S Rana, S Jain, JK Khalsa, ... Molecular and cellular biology 35 (17), 2932-2946, 2015 | 60 | 2015 |
| A universal bacteriophage T4 nanoparticle platform to design multiplex SARS-CoV-2 vaccine candidates by CRISPR engineering J Zhu, N Ananthaswamy, S Jain, H Batra, WC Tang, DA Lewry, ... Science advances 7 (37), eabh1547, 2021 | 45 | 2021 |
| A bacteriophage-based, highly efficacious, needle-and adjuvant-free, mucosal COVID-19 vaccine J Zhu, S Jain, J Sha, H Batra, N Ananthaswamy, PB Kilgore, EK Hendrix, ... MBio 13 (4), e01822-22, 2022 | 19 | 2022 |
| A sequestered fusion peptide in the structure of an HIV-1 transmitted founder envelope trimer N Ananthaswamy, Q Fang, W AlSalmi, S Jain, Z Chen, T Klose, Y Sun, ... Nature communications 10 (1), 873, 2019 | 18 | 2019 |
| Humoral response to the HIV-1 envelope V2 region in a Thai early acute infection cohort HV Trinh, N Gohain, PT Pham, C Hamlin, H Song, E Sanders-Buell, ... Cells 8 (4), 365, 2019 | 10 | 2019 |
| Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial JL Vos, B Burman, S Jain, CWR Fitzgerald, EJ Sherman, LA Dunn, ... Nature medicine 29 (12), 3077-3089, 2023 | 9 | 2023 |
| Engineered Bacteriophage T4 Nanoparticle as a Potential Targeted Activator of HIV-1 Latency in CD4+ Human T-cells VBR Himanshu Batra, Jingen Zhu, Swati Jain, Neeti Ananthaswamy, Marthandan ... bioRxiv, 2021 | 8* | 2021 |
| CRISPR Engineering of Bacteriophage T4 to Design Vaccines Against SARS-CoV-2 and Emerging Pathogens VBR Jingen Zhu, Neeti Ananthaswamy, Swati Jain, Himanshu Batra, Wei-Chun Tang Thomas S. (eds) Vaccine Design. Methods in Molecular Biology 2410, 209-228, 2021 | 7* | 2021 |
| Nucleic acid vaccine platform for dengue and zika flaviviruses J Taslem Mourosi, A Awe, S Jain, H Batra Vaccines 10 (6), 834, 2022 | 6 | 2022 |
| A genetic shift in an escaped transmitted/founder virus guides combinatorial vaccine design against HIV-1 S Jain, G Uritskiy, M Mahalingam, H Batra, S Chand, H Trinh, C Beck, ... bioRxiv, 2021.06. 16.448593, 2021 | 3 | 2021 |
| A remarkable genetic shift in a transmitted/founder virus broadens antibody responses against HIV-1 S Jain, G Uritskiy, M Mahalingam, H Batra, S Chand, HV Trinh, C Beck, ... Elife 13, RP92379, 2024 | | 2024 |
| CD66b as a prognostic and predictive biomarker in patients with non-small cell lung cancer treated with checkpoint blockade immunotherapy S Jain, K Ma, LGT Morris Translational Cancer Research 12 (2), 447, 2023 | | 2023 |
| Design of HIV-1 Vaccine Guided by Mechanisms of Immune-Escape by Acute Viruses S Jain The Catholic University of America, 2020 | | 2020 |
| Correction: Trinh, HV, et al. Humoral Response to the HIV-1 Envelope V2 Region in a Thai Early Acute Infection Cohort. Cells 2019, 8, 365 HV Trinh, N Gohain, PT Pham, C Hamlin, H Song, E Sanders-Buell, ... Cells 8 (6), 2019 | | 2019 |
| An Escape Mutation in the V2 Region of the HIV Envelope Protein of a T/F Virus Guides Vaccine Design to Elicit Broadly Reactive V2-directed Antibodies S Jain, G Uritskiy, W AlSalmi, H Trinh, S Chand, M Mahalingam, G Kijak, ... AIDS RESEARCH AND HUMAN RETROVIRUSES 34, 330-330, 2018 | | 2018 |
| Topic review COVID-19 Vaccines Subjects: Others View times: 272 SJ SUBHASH CHAND | | |
